Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1(finding)
|
1 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.700 | 0 | ||||||||
Chorioretinal atrophy
|
4 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1 | 2014 | 2014 | ||||||
Endometriosis
|
274 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1 | 2013 | 2013 | ||||||
Lupus Erythematosus, Systemic
|
1172 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1 | 2019 | 2019 | ||||||
Malignant neoplasm of prostate
|
1082 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1 | 2014 | 2014 | ||||||
Prostate carcinoma
|
1168 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1 | 2014 | 2014 | ||||||
Renal Cell Carcinoma
|
288 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.020 | 0.500 | 2 | 2017 | 2017 | |||||
Conventional (Clear Cell) Renal Cell Carcinoma
|
222 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.030 | 0.667 | 3 | 2014 | 2017 | |||||
Diabetic Retinopathy
|
213 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.040 | 0.750 | 4 | 2013 | 2017 | |||||
Rheumatoid Arthritis
|
2387 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.040 | 0.750 | 4 | 2005 | 2013 | |||||
Age related macular degeneration
|
663 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.050 | 0.800 | 5 | 2009 | 2019 | |||||
Coronary Artery Disease
|
1577 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.060 | 0.833 | 6 | 2010 | 2018 | |||||
Diabetes Mellitus, Non-Insulin-Dependent
|
2672 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.040 | 1.000 | 4 | 2015 | 2018 | |||||
Coronary Arteriosclerosis
|
440 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.030 | 1.000 | 3 | 2010 | 2018 | |||||
Coronary heart disease
|
1178 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.030 | 1.000 | 3 | 2015 | 2018 | |||||
Glioma
|
353 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.030 | 1.000 | 3 | 2011 | 2018 | |||||
Neoplasms
|
1644 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.030 | 1.000 | 3 | 2013 | 2019 | |||||
Psoriasis
|
705 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.030 | 1.000 | 3 | 2014 | 2020 | |||||
Glioblastoma
|
281 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.020 | 1.000 | 2 | 2015 | 2018 | |||||
Glioblastoma Multiforme
|
186 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.020 | 1.000 | 2 | 2015 | 2018 | |||||
Hypertensive disease
|
1085 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.020 | 1.000 | 2 | 2015 | 2016 | |||||
Polycystic Ovary Syndrome
|
363 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.020 | 1.000 | 2 | 2016 | 2019 | |||||
Acute myocardial infarction
|
118 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Adult Glioblastoma
|
98 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Ankylosing spondylitis
|
609 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2016 | 2016 |